title: Therapeutic potential of chalcones as cardiovascular agents.
abstract: Cardiovascular diseases are the leading cause of death affecting 17.3 million people across the globe and are estimated to affect 23.3 million people by year 2030. In recent years, about 7.3 million people died due to coronary heart disease, 9.4 million deaths due to high blood pressure and 6.2 million due to stroke, where obesity and atherosclerotic progression remain the chief pathological factors. The search for newer and better cardiovascular agents is the foremost need to manage cardiac patient population across the world. Several natural and (semi) synthetic chalcones deserve the credit of being potential candidates to inhibit various cardiovascular, hematological and anti-obesity targets like angiotensin converting enzyme (ACE), cholesteryl ester transfer protein (CETP), diacylglycerol acyltransferase (DGAT), acyl-coenzyme A: cholesterol acyltransferase (ACAT), pancreatic lipase (PL), lipoprotein lipase (LPL), calcium (Ca(2+))/potassium (K(+)) channel, COX-1, TXA2 and TXB2. In this review, a comprehensive study of chalcones, their therapeutic targets, structure activity relationships (SARs), mechanisms of actions (MOAs) have been discussed. Chemically diverse chalcone scaffolds, their derivatives including structural manipulation of both aryl rings, replacement with heteroaryl scaffold(s) and hybridization through conjugation with other pharmacologically active scaffold have been highlighted. Chalcones which showed promising activity and have a well-defined MOAs, SARs must be considered as prototype for the design and development of potential anti-hypertensive, anti-anginal, anti-arrhythmic and cardioprotective agents. With the knowledge of these molecular targets, structural insights and SARs, this review may be helpful for (medicinal) chemists to design more potent, safe, selective and cost effective chalcone derivatives as potential cardiovascular agents.
authors.affiliation: Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, 495009, Chhattisgarh, India.
authors.forename: Debarshi Kar
authors.initials: DK
authors.lastname: Mahapatra
authors.affiliation: Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, 495009, Chhattisgarh, India. Electronic address: skbharti.ggu@gmail.com.
authors.forename: Sanjay Kumar
authors.initials: SK
authors.lastname: Bharti
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000737:chemistry / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000737:chemistry / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000737:chemistry* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D047188:Chalcones / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D013329:Structure-Activity Relationship
chemical_list: D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D047188:Chalcones
keywords: Anti-obesity; Anti-platelet; Cardiovascular; Chalcones; Hematological; Structure activity relationships (SARs)